Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 205-812-0 | CAS number: 153-00-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
There are no repeat-dose studies with ZK 5466. Read-across to results of studies with metenolone acetate (ZK 5469):
Subcutaneous, 2 weeks (Rat, non-GLP, dose: 0/ 4 mg, once daily): no effect
[Schering AG, 1960-11-29]
Subcutaneous, 26 weeks (Rat, non-GLP, doses: 0/ 0.33/ 3/ 10 mg/kg, every second day): NOEL < 0.33 mg/kg
[Schering AG, 1967-06-15]
Subcutaneous, 26 weeks (Dog-Beagle, non-GLP, doses: 0/ 6/ 20/ 40 mg/kg, every second day): NOEL: 6 mg/kg
[Schering AG, 1967-06-15]
Read-across to results of studies with ZK 5782 (metenolone enanthate):
Subcutaneous, 26 weeks (Rat, non-GLP, Doses: 0/ 1.5/ 15/ 50 mg/kg, once every second week; twice/week at high dose over last month): NOEL < 1.5 mg/kg
[Schering AG, 1962-02-07]
Subcutaneous, 26 weeks (Dog, non-GLP, Doses: 0/ 3/ 10 / 20 mg/kg, once every second week; twice/week at high dose over last month): NOEL = 20 mg/kg
[Schering AG, 1962-02-07]
Key value for chemical safety assessment
Additional information
There are no repeat-dose toxicity studies conducted with ZK 5466 (metenolone). Results of studies with metenolone acetate (ZK 5469) or methenolone enanthate (ZK 5782) are regarded as representative as most likely ester cleavage occurs in vivo.
In rats, the once daily subcutaneous administration of 4 mg ZK 5469 to male and female animals over 2 weeks did not show any compound-related effects on body weight, clinical sings, organ weights and histopathological examination. [Schering AG, 1960-11-29]
After subcutaneous administration of ZK 5469 at doses of 0.33, 3 and 10 mg/kg every second day over 26 weeks, the following effects were seen: mortality in females (at 10 mg/kg) increased body weight at >= 3.0 mg/kg, inhibition of spermatogenesis in the testes (at >= 0.33 mg/kg) and of follicle maturation in the ovaries (at >= 3 mg/kg) as well as renal damage associated with increased concrements in urinary bladder in females only at >= 3 mg/kg. Mortality in females at the high dose (60% of animals) was associated with increased concrements in urinary bladder. All findings described are regarded as exaggerated pharmacodynamic effects of ZK 5469. Due to testes findings, the NOEL is < 0.33 mg/kg. [Schering AG, 1967-06-15]
In dogs after subcutaneous administration of ZK 5649 at doses of 6, 20 and 40 mg/kg every second day no substance-related findings besides increased body weight (>= 20 mg/kg) and inhibition of spermatogenesis (40 mg/kg) were observed. These effects are known pharmacodynamic effects of an anabolic steroids. No findings were described at the lowest dose tested (6.0 mg/kg). [Schering AG, 1967-06-15]
Compound-related findings in rats after subcutaneous administration of ZK 5782 at doses of 1.5, 15 and 50 mg/kg once every second week over 26 weeks are regarded as exaggerated pharmacodynamic effects and correspond to those described for ZK 5469. They include effects on body weight (increased in females at >= 15 mg/kg; reduced in males at >= 50 mg/kg), endocrine organs (reduced weights of adrenals at >= 15 mg/kg in females, reduced weight of ovaries and atrophy at >= 15 mg/kg; reduced weight of uterus at >= 1.5 mg/kg; reduced testes weights and atrophy at >= 1.5 mg/kg) and kidneys (interstitial nephritis in both sexes at 50 mg/kg). No other signs of organ toxicity and especially no signs of liver toxicity were observed. The NOEL is < 1.5 mg/kg due to effects on endocrine organs. [Schering AG, 1962-02-07]
The subcutaneous administration of ZK 5782 to male and female dogs over 26 weeks at doses of 3, 10 and 20 mg/kg once every second week was well tolerated without compound-related findings. The highest tested dose of 20 mg/kg corresponds to the NOEL. [Schering AG, 1962-02-07]
Therapeutic dosages for metenolone acetate in humans are 2 to 3 mg/day per os. Some known side effects of chronic treatment with anabolics are disturbances to the electrolyte metabolism and liver function.
Justification for classification or non-classification
Based on the results there is no classification required according to Directive 67/548/EEC and Regulation (EC) 1272/2008 (CLP).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.